References
Bergsagel PL . A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia 2008; 22: 673–675.
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008; 22: 850–855.
Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. Blood 2007; 110: 74.
San Miguel JF, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007; 110: 76.
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al., Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al., Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.
Jawed I, Lee CM, Tward JD, Macdonald OK, Martincic D, Vudarla N et al. Survival outcomes for multiple myeloma over three decades: a surveillance, epidemiology, and end results (SEER) analysis. J Clin Oncol 2007; 25 (18s): 8019.
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Richardson, P., San-Miguel, J., Lonial, S. et al. The research mission in myeloma. Leukemia 23, 422–423 (2009). https://doi.org/10.1038/leu.2008.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.209
- Springer Nature Limited
This article is cited by
-
Reply to the research mission in myeloma by Richardson et al.
Leukemia (2009)